These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7894482)

  • 1. Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy.
    Cox GA; Sunada Y; Campbell KP; Chamberlain JS
    Nat Genet; 1994 Dec; 8(4):333-9. PubMed ID: 7894482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exogenous Dp71 restores the levels of dystrophin associated proteins but does not alleviate muscle damage in mdx mice.
    Greenberg DS; Sunada Y; Campbell KP; Yaffe D; Nudel U
    Nat Genet; 1994 Dec; 8(4):340-4. PubMed ID: 7894483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.
    Gardner KL; Kearney JA; Edwards JD; Rafael-Fortney JA
    Gene Ther; 2006 May; 13(9):744-51. PubMed ID: 16307000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex.
    Judge LM; Haraguchiln M; Chamberlain JS
    J Cell Sci; 2006 Apr; 119(Pt 8):1537-46. PubMed ID: 16569668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute pathophysiological effects of muscle-expressed Dp71 transgene on normal and dystrophic mouse muscle.
    Wieneke S; Heimann P; Leibovitz S; Nudel U; Jockusch H
    J Appl Physiol (1985); 2003 Nov; 95(5):1861-6. PubMed ID: 14555666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exogenous Dp71 is a dominant negative competitor of dystrophin in skeletal muscle.
    Leibovitz S; Meshorer A; Fridman Y; Wieneke S; Jockusch H; Yaffe D; Nudel U
    Neuromuscul Disord; 2002 Nov; 12(9):836-44. PubMed ID: 12398834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between dystrophin and the sarcolemma membrane.
    Chamberlain JS; Corrado K; Rafael JA; Cox GA; Hauser M; Lumeng C
    Soc Gen Physiol Ser; 1997; 52():19-29. PubMed ID: 9210217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene.
    Sakamoto M; Yuasa K; Yoshimura M; Yokota T; Ikemoto T; Suzuki M; Dickson G; Miyagoe-Suzuki Y; Takeda S
    Biochem Biophys Res Commun; 2002 May; 293(4):1265-72. PubMed ID: 12054513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins.
    Tidball JG; Wehling-Henricks M
    Mol Genet Metab; 2004 Aug; 82(4):312-20. PubMed ID: 15308129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcoglycans in muscular dystrophy.
    Hack AA; Groh ME; McNally EM
    Microsc Res Tech; 2000 Feb 1-15; 48(3-4):167-80. PubMed ID: 10679964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
    Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
    Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dystrophin and utrophin: genetic analyses of their role in skeletal muscle.
    Rafael JA; Brown SC
    Microsc Res Tech; 2000 Feb 1-15; 48(3-4):155-66. PubMed ID: 10679963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity.
    Cox GA; Cole NM; Matsumura K; Phelps SF; Hauschka SD; Campbell KP; Faulkner JA; Chamberlain JS
    Nature; 1993 Aug; 364(6439):725-9. PubMed ID: 8355788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF-II ameliorates the dystrophic phenotype and coordinately down-regulates programmed cell death.
    Smith J; Goldsmith C; Ward A; LeDieu R
    Cell Death Differ; 2000 Nov; 7(11):1109-18. PubMed ID: 11139285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe muscular dystrophy in mice that lack dystrophin and alpha7 integrin.
    Rooney JE; Welser JV; Dechert MA; Flintoff-Dye NL; Kaufman SJ; Burkin DJ
    J Cell Sci; 2006 Jun; 119(Pt 11):2185-95. PubMed ID: 16684813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deficiency of dystrophin-associated proteins in Duchenne muscular dystrophy patients lacking COOH-terminal domains of dystrophin.
    Matsumura K; Tomé FM; Ionasescu V; Ervasti JM; Anderson RD; Romero NB; Simon D; Récan D; Kaplan JC; Fardeau M
    J Clin Invest; 1993 Aug; 92(2):866-71. PubMed ID: 8349821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAPON expression in skeletal muscle is regulated by position, repair, NOS activity, and dystrophy.
    Ségalat L; Grisoni K; Archer J; Vargas C; Bertrand A; Anderson JE
    Exp Cell Res; 2005 Jan; 302(2):170-9. PubMed ID: 15561099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant-negative inhibition of Ca2+ influx via TRPV2 ameliorates muscular dystrophy in animal models.
    Iwata Y; Katanosaka Y; Arai Y; Shigekawa M; Wakabayashi S
    Hum Mol Genet; 2009 Mar; 18(5):824-34. PubMed ID: 19050039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles.
    Floyd SS; Clemens PR; Ontell MR; Kochanek S; Day CS; Yang J; Hauschka SD; Balkir L; Morgan J; Moreland MS; Feero GW; Epperly M; Huard J
    Gene Ther; 1998 Jan; 5(1):19-30. PubMed ID: 9536261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mouse dystrophin muscle promoter/enhancer drives expression of mini-dystrophin in transgenic mdx mice and rescues the dystrophy in these mice.
    Anderson CL; De Repentigny Y; Cifelli C; Marshall P; Renaud JM; Worton RG; Kothary R
    Mol Ther; 2006 Nov; 14(5):724-34. PubMed ID: 16807118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.